Evidence map›Paper›PMID 22689290›Full record

Trial reportDepression and anxiety2012

Long-term efficacy of repeated daily prefrontal transcranial magnetic stimulation (TMS) in treatment-resistant depression.

Antonio Mantovani, Martina Pavlicova, David Avery, Ziad Nahas, William M McDonald, Chandra D Wajdik, Paul E Holtzheimer, Mark S George, Harold A Sackeim, Sarah H Lisanby

Registry-linked trialOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Depression and anxiety, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04210557 (Models of Auditory Hallucination), which is not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04210557 naterminatednot on this mapstarted 2020, after this paper: background citation

Models of Auditory Hallucination

TypeinterventionalSponsorYale UniversityRan2020 to 2021Enrolled1ConditionsSchizophrenia, Schizo Affective Disorder, Auditory HallucinationArmsTranscranial Magnetic Stimulation (TMS)
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. The Care of Patients With Complex Mood Disorders.Focus (American Psychiatric Publishing) · 2020
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Bibliography: Depression: Challenges and Treatments.Focus (American Psychiatric Publishing) · 2016
    Article
  14. Review
  15. Transcranial magnetic stimulation in the treatment of substance addiction.Annals of the New York Academy of Sciences · 2014
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 3 countries.

Antonio MantovaniDepartment of Psychiatry, Columbia University College of Physicians and Surgeons/New York State Psychiatric Institute, New York, New York 10032, USA. am2518@columbia.edu
Martina Pavlicova
David Avery
Ziad Nahas
William M McDonald
Chandra D Wajdik
Paul E Holtzheimer
Mark S George
Harold A Sackeim
Sarah H Lisanby
University of Washington · USAmerican University of Beirut · LBDartmouth–Hitchcock Medical Center · USDuke University · USEmory University · USNew York Psychoanalytic Society and Institute · USNew York State Psychiatric InstituteRalph H. Johnson VA Medical Center · USUniversity of Siena · IT

Funding

Optimization of TMS for Depression - Coordinating CenterR01MH069887 · NIMH · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI GEORGE, MARK S · 2004 to 2009
$2.4M
Optimization of Transcranial Magnetic Stimulation for DepressionR01MH069895 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI LISANBY, SARAH H · 2004 to 2009
$1.8M
Optimization of TMS for DepressionR01MH069929 · NIMH · UNIVERSITY OF WASHINGTON · PI AVERY, DAVID H · 2004 to 2009
$1.4M
Optimization of TMS for DepressionR01MH069896 · NIMH · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI GEORGE, MARK S · 2004 to 2009
$1.4M
Optimization of TMS for DepressionR01MH069886 · NIMH · EMORY UNIVERSITY · PI MCDONALD, WILLIAM M · 2004 to 2007
$1.3M
Investigating structural-functional brain abnormalities in late-life depressionK23MH077869 · NIMH · EMORY UNIVERSITY · PI HOLTZHEIMER, PAUL E · 2007 to 2010
$687k
NIMH NIH HHS 5R01MH069886NIMH NIH HHS 5R01MH069887NIMH NIH HHS 5R01MH069895NIMH NIH HHS 5R01MH069896NIMH NIH HHS 5R01MH069929NIMH NIH HHS K23 MH077869NIMH NIH HHS R01 MH069886NIMH NIH HHS R01 MH069887NIMH NIH HHS R01 MH069895NIMH NIH HHS R01 MH069896NIMH NIH HHS R01 MH069929
6 · The paper itself

Abstract

backgroundA few studies have examined the durability of transcranial magnetic stimulation (TMS) antidepressant benefit once patients remitted. This study examined the long-term durability of clinical benefit from TMS using a protocol-specified TMS taper and either continuation pharmacotherapy or naturalistic follow-up.

methodsPatients were remitters from an acute double-blind sham-controlled trial of TMS (n = 18), or from an open-label extension in patients who did not respond to the acute trial (n = 43). Long-term durability of TMS acute effect was examined in remitters over a 12-week follow-up. Relapse, defined as 24-item Hamilton Depression Rating Scale (HDRS-24) ≥20, was the primary outcome.

resultsOf 61 remitters in the acute trial, five entered naturalistic follow-up and 50 entered the TMS taper. Thirty-two patients completed TMS taper and 1-, 2-, and 3-month follow-up. At 3-month visit, 29 of 50 (58%) were classified as in remission (HDRS-24 ≤10), two of 50 (4%) as partial responders (30%≤ HDRS-24 reduction <50% from baseline), and one of 50 (2%) met criteria for relapse. During the entire 3-month follow-up, five of the 37 patients relapsed (relapse rate = 13.5%), but four of them regained remission by the end of the study. The average time to relapse in these five patients was 7.2 ± 3.3 weeks. Patients who relapsed had higher depression scores at 1 month.

conclusionsWhile one third of the sample was lost to follow-up, our results demonstrate that most patients contributing to observations experienced persistence of benefit from TMS followed by pharmacotherapy or no medication. Longer follow-up and more rigorous studies are needed to explore the true long-term durability of remission produced by TMS.

Indexed as

Depressive Disorder, Treatment-ResistantDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMiddle AgedPrefrontal CortexPsychiatric Status Rating ScalesSecondary PreventionTranscranial Magnetic StimulationTreatment Outcome

Identifiers

PMID22689290
PMCPMC4413472
OpenAlexW2105833814

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.